title: Glucocorticoids, cytokines and brain abnormalities in depression.
abstract: Major depression (MD) is a common psychiatric disorder with a complex and multifactor aetiology. Potential mechanisms associated with the pathogenesis of this disorder include monoamine deficits, hypothalamic-pituitary-adrenal (HPA) axis dysfunctions, inflammatory and/or neurodegenerative alterations. An increased secretion and reactivity of cortisol together with an altered feedback inhibition are the most widely observed HPA abnormalities in MD patients. Glucocorticoids, such as cortisol, are vital hormones that are released in response to stress, and regulate metabolism and immunity but also neuronal survival and neurogenesis. Interestingly depression is highly prevalent in infectious, autoimmune and neurodegenerative diseases and at the same time, depressed patients show higher levels of pro-inflammatory cytokines. Since communication occurs between the endocrine, immune and central nervous system, an activation of the inflammatory responses can affect neuroendocrine processes, and vice versa. Therefore, HPA axis hyperactivity and inflammation might be part of the same pathophysiological process: HPA axis hyperactivity is a marker of glucocorticoid resistance, implying ineffective action of glucocorticoid hormones on target tissues, which could lead to immune activation; and, equally, inflammation could stimulate HPA axis activity via both a direct action of cytokines on the brain and by inducing glucocorticoid resistance. In addition, increased levels of pro-inflammatory cytokines also induce the production of neurotoxic end products of the tryptophan-kynurenine pathway. Although the evidence for neurodegeneration in MD is controversial, depression is co-morbid with many other conditions where neurodegeneration is present. Since several systems seem to be involved interacting with each other, we cannot unequivocally accept the simple model that glucocorticoids induce neurodegeneration, but rather that elevated cytokines, in the context of glucocorticoid resistance, are probably the offenders. Chronic inflammatory changes in the presence of glucocorticoid resistance may represent a common feature that could be responsible for the enhanced vulnerability of depressed patients to develop neurodegenerative changes later in life. However, further studies are needed to clarify the relative contribution of glucocorticoids and inflammatory signals to MD and other disorders.
authors.affiliation: Stress, Psychiatry and Immunology Laboratory (SPI-Lab), Department of Psychological Medicine, Institute of Psychiatry, King's College London, 125 Coldharbour Lane, SE59NU London, United Kingdom. patricia.zunszain@kcl.ac.uk
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Zunszain
authors.forename: Christoph
authors.initials: C
authors.lastname: Anacker
authors.forename: Annamaria
authors.initials: A
authors.lastname: Cattaneo
authors.forename: Livia A
authors.initials: LA
authors.lastname: Carvalho
authors.forename: Carmine M
authors.initials: CM
authors.lastname: Pariante
mesh_terms: D000818:Animals; D001921:Brain / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism*; D003863:Depression / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D005938:Glucocorticoids / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D009410:Nerve Degeneration / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D019636:Neurodegenerative Diseases / Q000378:metabolism
chemical_list: D016207:Cytokines; D005938:Glucocorticoids
references.citation: Oncogene. 2006 Oct 30;25(51):6758-80
references.pmid: 17072327
references.citation: Ann N Y Acad Sci. 1999;896:30-47
references.pmid: 10681886
references.citation: J Neurosci. 2003 Jul 2;23(13):5536-44
references.pmid: 12843254
references.citation: Br J Psychiatry. 2009 Aug;195(2):102-8
references.pmid: 19648538
references.citation: J Psychosom Res. 2007 Aug;63(2):131-5
references.pmid: 17662748
references.citation: J Neuroendocrinol. 2003 Aug;15(8):811-2
references.pmid: 12834443
references.citation: PLoS One. 2009;4(1):e4266
references.pmid: 19180238
references.citation: Neuron. 2009 May 28;62(4):479-93
references.pmid: 19477151
references.citation: Front Neuroendocrinol. 1993 Apr;14(2):76-122
references.pmid: 8387436
references.citation: Ann N Y Acad Sci. 2009 Oct;1179:167-78
references.pmid: 19906239
references.citation: J Clin Psychiatry. 2000;61 Suppl 6:4-6
references.pmid: 10775017
references.citation: Neuroscience. 2005;135(3):659-78
references.pmid: 16154288
references.citation: Endocrinology. 1999 Sep;140(9):4359-66
references.pmid: 10465310
references.citation: Mol Psychiatry. 2008 Jul;13(7):717-28
references.pmid: 17700577
references.citation: J Psychopharmacol. 2006 Jul;20(4 Suppl):79-84
references.pmid: 16785275
references.citation: Mol Psychiatry. 2005 Apr;10(4):332-3
references.pmid: 15655564
references.citation: Biol Psychiatry. 2003 Sep 1;54(5):499-503
references.pmid: 12946878
references.citation: Semin Neonatol. 2003 Feb;8(1):83-91
references.pmid: 12667833
references.citation: Am J Psychiatry. 2003 Oct;160(10):1890-1
references.pmid: 14514508
references.citation: Stress. 2008 Nov;11(6):411-24
references.pmid: 19065455
references.citation: Am J Psychiatry. 1971 Jul;128(1):31-40
references.pmid: 4949651
references.citation: Genes Brain Behav. 2008 Feb;7 Suppl 1:28-42
references.pmid: 18184368
references.citation: Mol Psychiatry. 2010 Apr;15(4):404-14
references.pmid: 19773812
references.citation: Neuropsychopharmacology. 2008 Dec;33(13):3182-9
references.pmid: 18368033
references.citation: Eur Arch Psychiatry Clin Neurosci. 1992;241(5):317-22
references.pmid: 1606197
references.citation: Science. 1984 Dec 14;226(4680):1342-4
references.pmid: 6334362
references.citation: Brain Behav Immun. 2009 Aug;23(6):750-4
references.pmid: 19258033
references.citation: Neuropsychopharmacology. 2009 Feb;34(3):747-58
references.pmid: 18784648
references.citation: Prog Brain Res. 2007;163:339-54
references.pmid: 17765728
references.citation: Eur J Neurosci. 2001 Nov;14(10):1603-12
references.pmid: 11860455
references.citation: Arch Gen Psychiatry. 1992 May;49(5):384-7
references.pmid: 1586274
references.citation: J Psychiatry Neurosci. 2009 Jan;34(1):41-54
references.pmid: 19125212
references.citation: Psychosom Med. 2009 Feb;71(2):171-86
references.pmid: 19188531
references.citation: Med Hypotheses. 1991 Aug;35(4):298-306
references.pmid: 1943879
references.citation: Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):751-6
references.pmid: 18178625
references.citation: Brain Res Rev. 2009 Oct;61(2):105-23
references.pmid: 19481572
references.citation: Brain Behav Immun. 2010 Jan;24(1):19-30
references.pmid: 19647070
references.citation: Biol Psychiatry. 2001 Mar 1;49(5):391-404
references.pmid: 11274650
references.citation: Biol Psychiatry. 2004 Aug 1;56(3):137-9
references.pmid: 15271580
references.citation: Biol Psychiatry. 2009 May 1;65(9):732-41
references.pmid: 19150053
references.citation: Metabolism. 2005 May;54(5 Suppl 1):20-3
references.pmid: 15877308
references.citation: Neuroimmunomodulation. 2009;16(5):300-17
references.pmid: 19571591
references.citation: Nat Rev Neurosci. 2005 Jun;6(6):463-75
references.pmid: 15891777
references.citation: CNS Drugs. 2005;19(2):105-23
references.pmid: 15697325
references.citation: Biol Psychiatry. 2003 Aug 1;54(3):338-52
references.pmid: 12893109
references.citation: Psychol Med. 1994 Feb;24(1):167-77
references.pmid: 8208882
references.citation: Biol Psychiatry. 2004 Nov 1;56(9):640-50
references.pmid: 15522247
references.citation: Neurosci Biobehav Rev. 2009 Mar;33(3):355-66
references.pmid: 18996146
references.citation: Br J Psychiatry. 1994 Mar;164(3):365-71
references.pmid: 7832833
references.citation: Med Hypotheses. 2003 Nov-Dec;61(5-6):519-25
references.pmid: 14592780
references.citation: Psychopharmacology (Berl). 2006 Dec;189(2):225-35
references.pmid: 17016711
references.citation: Neuroscience. 2009 Jan 23;158(2):823-32
references.pmid: 19007863
references.citation: Mol Cell Endocrinol. 2009 Mar 5;300(1-2):2-6
references.pmid: 18840500
references.citation: J Psychiatry Neurosci. 2009 Jan;34(1):4-20
references.pmid: 19125209
references.citation: Arch Gen Psychiatry. 2003 Dec;60(12):1248-55
references.pmid: 14662557
references.citation: Adv Exp Med Biol. 1999;461:107-16
references.pmid: 10442170
references.citation: Psychol Med. 2010 Jan;40(1):1-4
references.pmid: 19335939
references.citation: Nat Neurosci. 2007 Sep;10(9):1110-5
references.pmid: 17726477
references.citation: Br J Psychiatry. 2004 Jul;185:5-10
references.pmid: 15231549
references.citation: Prog Neurobiol. 2008 May;85(1):1-74
references.pmid: 18346832
references.citation: Neuropsychopharmacology. 2009 Oct;34(11):2376-89
references.pmid: 19606083
references.citation: Trends Immunol. 2006 Jan;27(1):24-31
references.pmid: 16316783
references.citation: Biol Psychiatry. 2008 Aug 15;64(4):293-301
references.pmid: 18406399
references.citation: Psychiatry Res. 1991 Aug;38(2):163-71
references.pmid: 1661430
references.citation: Mol Endocrinol. 2009 Mar;23(3):281-91
references.pmid: 19095768
references.citation: Curr Opin Psychiatry. 2008 May;21(3):290-5
references.pmid: 18382230
references.citation: J Neuroendocrinol. 2006 Jun;18(6):393-411
references.pmid: 16684130
references.citation: Biol Psychiatry. 2010 Mar 1;67(5):446-57
references.pmid: 20015486
references.citation: Front Neuroendocrinol. 2007 Aug-Sep;28(2-3):72-96
references.pmid: 17544065
references.citation: Schizophr Res. 2010 Feb;116(2-3):234-42
references.pmid: 19751968
references.citation: Am J Psychiatry. 2004 Apr;161(4):598-607
references.pmid: 15056502
references.citation: Immunol Allergy Clin North Am. 2009 May;29(2):285-93
references.pmid: 19389582
references.citation: Nat Rev Neurosci. 2008 Jan;9(1):46-56
references.pmid: 18073775
references.citation: Brain Behav Immun. 2007 Jan;21(1):9-19
references.pmid: 17070667
references.citation: Mol Psychiatry. 2000 May;5(3):262-9
references.pmid: 10889528
references.citation: Eur Neuropsychopharmacol. 2010 Jan;20(1):1-17
references.pmid: 19748235
references.citation: CNS Spectr. 2006 Dec;11(12 Suppl 15):12-21
references.pmid: 17146414
references.citation: J Affect Disord. 1982 Jun;4(2):93-101
references.pmid: 6213695
references.citation: Biol Psychiatry. 2004 Dec 1;56(11):819-24
references.pmid: 15576057
references.citation: Hippocampus. 2006;16(3):233-8
references.pmid: 16411244
references.citation: Mol Psychiatry. 2005 Jun;10(6):538-44
references.pmid: 15494706
references.citation: Neuropsychopharmacology. 2005 Oct;30(10):1923-31
references.pmid: 15956995
references.citation: J Clin Psychiatry. 1998;59 Suppl 14:11-4
references.pmid: 9818625
references.citation: Isr J Med Sci. 1995 Dec;31(12):705-12
references.pmid: 8543464
references.citation: Psychoneuroendocrinology. 2008 Jan;33(1):108-17
references.pmid: 18037570
references.citation: Cell. 2008 Feb 22;132(4):645-60
references.pmid: 18295581
references.citation: Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):168-79
references.pmid: 17237843
references.citation: Am J Psychiatry. 2004 Nov;161(11):1957-66
references.pmid: 15514393
references.citation: Biol Psychiatry. 2004 Aug 1;56(3):140-5
references.pmid: 15271581
references.citation: Eur Arch Psychiatry Clin Neurosci. 2007 Aug;257(5):250-60
references.pmid: 17401728
references.citation: Biol Psychiatry. 2008 Aug 15;64(4):266-72
references.pmid: 18440494
references.citation: Psychopharmacology (Berl). 2005 Oct;182(1):54-7
references.pmid: 15991000
references.citation: J Psychosom Res. 1966 Sep;10(2):189-95
references.pmid: 5969513
references.citation: Neuropsychopharmacology. 2007 Dec;32(12):2520-9
references.pmid: 17356567
references.citation: Mol Psychiatry. 2007 Nov;12(11):988-1000
references.pmid: 17457312
references.citation: Arch Gen Psychiatry. 2000 Oct;57(10):925-35
references.pmid: 11015810
references.citation: Mol Psychiatry. 2006 May;11(5):514-22
references.pmid: 16415915
references.citation: Neurochem Res. 2007 Oct;32(10):1749-56
references.pmid: 17705097
references.citation: Mol Psychiatry. 2009 May;14(5):511-22
references.pmid: 18195714
references.citation: Acta Psychiatr Scand. 1991 Oct;84(4):379-86
references.pmid: 1746291
references.citation: Psychopharmacology (Berl). 2008 Aug;199(2):231-44
references.pmid: 18491079
references.citation: J Psychiatry Neurosci. 2004 Jan;29(1):11-7
references.pmid: 14719046
references.citation: Endocr Rev. 1986 Aug;7(3):284-301
references.pmid: 3527687
references.citation: Mol Psychiatry. 2009 Dec;14(12):1095-104
references.pmid: 18458677
references.citation: Ann N Y Acad Sci. 2009 Oct;1179:86-105
references.pmid: 19906234
references.citation: Trends Neurosci. 2008 Sep;31(9):464-8
references.pmid: 18675469
references.citation: Metab Brain Dis. 2009 Mar;24(1):27-53
references.pmid: 19085093
references.citation: Int J Neuropsychopharmacol. 2002 Dec;5(4):389-99
references.pmid: 12466037